175
Participants
Start Date
June 30, 2005
Primary Completion Date
November 30, 2006
Study Completion Date
November 30, 2006
MenACWY-CRM
Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
MenC-CRM
One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
DTaP-Hib-IPV
PC7
One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
MMR
Varicella
Children's Hospital of Eastern Ontario Research Institute, Ottawa
Herridge Community Health Clinic, Ottawa
Clinical Trials Research Center, Department of Pediatrics, Dalhousie University, IWK Health Center, Halifax
Lead Sponsor
Novartis Vaccines
INDUSTRY